Protein therapeutics and clinical intelligence for CNS disorders.
AI screening and decision-support tools for neurological and ENT conditions. DBS candidacy assessment, Parkinson's progression prediction, ear disease diagnosis. Revenue through hospital partnerships.
De novo design of therapeutic proteins targeting CNS disorders. Uses RFdiffusion, ProteinMPNN, and AlphaFold to create BBB-crossing biologics. The long-term R&D play.
AI-assisted ear disease diagnosis from otoscopic images. Upload an image and get an instant screening result.
Try LiveMultimodal deep brain stimulation outcome predictor using multi-source patient data.
Try LiveDBS candidacy screening tool for Parkinson's patients. Determines suitability for deep brain stimulation.
Try LiveProtein-ligand binding affinity prediction. Predicts how strongly a drug binds to its protein target.
Try LiveBlood-brain barrier permeability prediction. Assesses whether compounds can cross the BBB to reach the CNS.
Try LiveA world where neurological diseases are detected early and treated with precision-designed protein therapeutics.
By 2029, we aim to deploy AI screening tools in 50 Korean hospitals and advance 2 novel protein therapeutics into preclinical validation.
The Name: Ratan Bio is named after the founder's father, Ratan - a word meaning "jewel" in Punjabi and Hindi. The company carries his name as a tribute and a promise.
Korea allocated ₩3.46 trillion to startups in 2026. Non-dilutive funding through TIPS, K-Startup Grand Challenge, Deep Tech Package.
Samsung Biologics, Celltrion, and 200+ biotech companies form a rich ecosystem for partnerships and talent.
Gachon Cocone School provides startup mentoring, workspace, funding up to ₩150M, and investor access for research-based ventures.
National priority on AI + bio-health convergence with dedicated government funding tracks.
5 deployed AI products. Expertise in protein engineering, computational biology, and explainable AI.
M.S. and B.S. in Biotechnology, Shoolini University, India (Top 500 Globally in 7 subject areas - QS World University Rankings by Subject 2026).
CEO Lipidomia Co., Ltd. Former Associate Research Scientist at Columbia University and Cardiovascular Pharmacology Scientist at Pfizer USA. Ph.D./M.S. Rutgers University, B.S. Korea University. ~100 research papers, 10 patents. Editorial Board Member of Journal of Biological Chemistry and Journal of Lipid Research.
Korean market entry, grant compliance, and regulatory affairs.
B.S. in Life Sciences, Gachon University.
AI tools for neurological disease diagnosis combined with therapeutic protein design. We have 5 deployed products covering neurology, ENT diagnostics, and drug discovery.
Gachon University, Seongnam-si, South Korea - operating from the Lipid Biochemistry Lab.
Yes! All 5 products are live and publicly accessible. Check the Products section above for direct links.
We are currently in the pre-incorporation phase, planning to incorporate in early 2027. We are actively seeking pilot partners.
Founded by Kartic, a PhD candidate at Gachon University, and advised by Prof. Tae-sik Park, Dean of Research Affairs.
Reach out at [email protected]. We welcome collaborations with university hospitals and biotech companies.
Ratan Bio is currently in pre-incorporation phase. We are actively seeking pilot partners in Korean university hospitals and biotech companies. If you are interested in collaborating, we would love to hear from you.